The US fibrinogen concentrates market is projected to grow from $512 million in 2020 to $1,174 million by 2035. Steady revenue growth is attributed to expanding indications, increased hospital use, and technological advancements in product purification. The CAGR of 8.4% reflects both rising demand and continuous product innovation, particularly in complex surgical and trauma care. Larger hospital systems and integrated health networks are adopting new-generation fibrinogen products at accelerated rates.
Read More - https://bussinessinsights.com/research-report/us-fibrinogen-concentrates
Surgical procedures dominate the application share within the US fibrinogen concentrates segment for 2025, owing to the critical role of hemostasis in complex and elective surgeries. Trauma management follows, reflecting the growing reliance on fibrinogen in emergency medicine. Both congenital and acquired fibrinogen deficiency treatments continue to expand steadily as awareness and diagnoses rise. Obstetric bleeding and other specialty indications collectively make up an important, albeit smaller, portion of total usage—highlighting ongoing diversification of clinical use cases.
Request Free Sample- https://bussinessinsights.com/request/telecommunication/us-fibrinogen-concentrates
Who are the key players in US Fibrinogen Concentrates industry?
Major players in the US fibrinogen concentrates market include CSL Behring, Grifols, Octapharma, LFB, and Bio Products Laboratory. These companies focus on plasma-derived therapies for treating bleeding disorders, offering FDA-approved fibrinogen concentrate products, and driving innovation through ongoing research and development in hemostatic agents.
What is the US Fibrinogen Concentrates growth?
The US fibrinogen concentrates market has shown steady growth, particularly due to increased approvals of products like CSL Behring’s RiaSTAP and the rising incidence of bleeding disorders. Expanded indications and heightened awareness about acute bleeding management are further boosting demand in recent years.
Which segment accounted for the largest US Fibrinogen Concentrates share?
The largest share in the US fibrinogen concentrates market is held by the surgical and trauma applications segment. This is driven by a high demand for fibrinogen concentrates in managing perioperative bleeding and trauma-induced coagulopathy, where rapid restoration of clotting factors is essential for positive patient outcomes.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com